EACS2023: 563 CAB + RPV long-acting antiretroviral therapy: real world data from an Italian single center in Rome V. Iannone , F. Lombardi , P.F. Salvo , D. Farinacci , G. Baldin , A. Carbone , M. Petrucci , F. Onorati , E. Visconti , S. Di Giambenedetto Università Cattolica del Sacro Cuore, Dipartimento di Malattie Infettive, Roma, Italy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Malattie Infettive, Roma, Italy General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Long-acting antiretroviral injectable CAB+RPV (CARLA) has the potential to maintain viral suppression in treatment experienced PLWHV, overcoming the adherence barriers to the daily oral treatment. Our aim was to describe ARTexperienced, virologically suppressed PLWH who switched from oral ART to CARLA and currently attending our outpatient clinic of infectious diseases, in Rome. Method: We conducted a longitudinal prospective study, enrolling 38 virologically suppressed PLWH, from October 2022 to May 2023. Only one participant underwent the once daily oral lead-in phase. We collected individuals’ clinical history, viroimmunological and metabolic parameters at different time point: baseline (time of switch), 4W, 12W and 28W. Results: Our population was mainly composed by males (71,1%), Italians (94.7%), with a median age of 49.6 (IQR 38.1-58.0) years. At baseline, all participants had an HIV-RNA undetectable; median of CD4+ cell count at baseline was 713 cell/mm3 (IQR 489-848) while median CD4/CD8 ratio was 1.11 (IQR 0.77-1.45). The participants’ characteristics at BL are summarized in Figure 2. All the participants maintained undetectable HIV-RNA until the 28W. Regarding to the immunological parameters, we did not observe a relevant variation in absolute CD4+ cell count or CD4/CD8 ratio during follow-up period (Figure 1). We did not find any main changes in lipid profile at 28W. Overall, most frequent side effect observed was pain in injection-site, radiated down the leg, which regresses in 24/48 hours upon administration of nonsteroidal anti-inflammatory drugs. Only one patient reported fever after the second parenteral administration. No discontinuation was observed at 28W. Conclusions: Our real-world data confirms the potential in maintaining virological suppression of this new Injectable antiretroviral therapy. However, these data needs to be evaluated in a larger cohort with a longer follow up. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 1 1 2 1 2 2 2 2 1 2 132 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=